Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
males and females 18 years of age or over
diagnosis of adult GHD for at least 6 months, or patients who have hypopituitarism from surgical resection
treated with a stable dose of daily rhGH for at least 3 months prior to screening
stable, adequate doses of replacement hormones (adrenal, thyroid, estrogen, testosterone, vasopressin) for at least 3 months prior to screening
* Other criteria apply, please contact the investigator for more information
You may not be if
patients with acute or chronic conditions or diseases that could confound results of the study or put the patient at undue risk as determined by the investigator
Presence of contraindications to rhGH treatment
patients who have participated in another clinical trial with a new chemical/biological entity within 3 months of screening
patients with known active malignancy (excluding surgically removed basal cell carcinoma or carcinoma in situ of cervix) d. patients with a previously treated pituitary tumor with evidence of tumor progression in the past year
patients with a new diagnosis of pituitary adenoma or other intracranial tumor within 12 months of screening
presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in the past year.
patients with type 1 diabetes mellitus oror poorly controlled type 2 diabetes mellitus as indicated by a glycated hemoglobin (HbA1c) ≥8%
patients using weight reducing agents or appetite suppressants
* Other criteria apply, please contact the investigator for more information
Clareo Health | Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
